O Bairey1, O Benjamini, D Blickstein, A Elis, R Ruchlemer. 1. Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Department of Internal Medicine A, Sapir Medical Center, Kfar Saba, Israel. bernhard.pestalozzi@usz.ch
Abstract
BACKGROUND: Very elderly patients (> or =80 years old) with non-Hodgkin's lymphoma (NHL) frequently have co-morbid conditions and are generally excluded from clinical trials or even from treatment. The optimal treatment of these patients is unknown. PATIENTS AND METHODS: We reviewed the records of 109 patients > or =80 years at diagnosis of NHL (65 F/44 M; median age: 84 years, range; 80-95). RESULTS: Seventy-eight patients (72%) had aggressive NHL, 25 (23%) had indolent and NHL, eight had unclassified disease. Advanced-stage disease was noted in 54%. Forty patients (39%) had a poor ECOG performance status (PS), and 52 (49%) had an intermediate or high risk International Prognostic Index (IPI). Seventy-nine patients (72%) were treated with chemotherapy and 37 (34%) with radiotherapy. Initial chemotherapy consisted of chlorambucil in 15, oral etoposide in 2, and combination protocol in 62. Only 16% of patients received full-dose therapy, and only 50% completed > or =6 cycles of combination chemotherapy. The overall response rate for the 69 evaluable patients was 84% (complete 56.5%, partial 27.5%). Overall 5-year survival for the whole group was 39%, and median survival time was 26 months. CONCLUSION: A high response rate can be achieved in very elderly NHL patients despite aggressive histology, poor prognostic features, and reduced doses of chemotherapy. Age alone should not be a contraindication to treatment.
BACKGROUND: Very elderly patients (> or =80 years old) with non-Hodgkin's lymphoma (NHL) frequently have co-morbid conditions and are generally excluded from clinical trials or even from treatment. The optimal treatment of these patients is unknown. PATIENTS AND METHODS: We reviewed the records of 109 patients > or =80 years at diagnosis of NHL (65 F/44 M; median age: 84 years, range; 80-95). RESULTS: Seventy-eight patients (72%) had aggressive NHL, 25 (23%) had indolent and NHL, eight had unclassified disease. Advanced-stage disease was noted in 54%. Forty patients (39%) had a poor ECOG performance status (PS), and 52 (49%) had an intermediate or high risk International Prognostic Index (IPI). Seventy-nine patients (72%) were treated with chemotherapy and 37 (34%) with radiotherapy. Initial chemotherapy consisted of chlorambucil in 15, oral etoposide in 2, and combination protocol in 62. Only 16% of patients received full-dose therapy, and only 50% completed > or =6 cycles of combination chemotherapy. The overall response rate for the 69 evaluable patients was 84% (complete 56.5%, partial 27.5%). Overall 5-year survival for the whole group was 39%, and median survival time was 26 months. CONCLUSION: A high response rate can be achieved in very elderly NHLpatients despite aggressive histology, poor prognostic features, and reduced doses of chemotherapy. Age alone should not be a contraindication to treatment.
Authors: Angela M Robertson; Alicia Y Vera; Manuel Gallardo; Robin A Pollini; Thomas L Patterson; Patricia Case; Lucie Nguyen; Steffanie A Strathdee Journal: Am J Addict Date: 2010 Jul-Aug
Authors: Jessica N Williams; Ashish Rai; Joseph Lipscomb; Jean L Koff; Loretta J Nastoupil; Christopher R Flowers Journal: Cancer Date: 2015-02-11 Impact factor: 6.860
Authors: Carla Casulo; Jesse G Dixon; Fang-Shu Ou; Eva Hoster; Bruce A Peterson; Howard S Hochster; Pauline Brice; Marco Ladetto; Wolfgang Hiddemann; Robert Marcus; Eva Kimby; Michael Herold; Tina Nielsen; Franck Morschhauser; Mathias Rummel; Anton Hagenbeek; Umberto Vitolo; Gilles A Salles; Qian Shi; Christopher R Flowers Journal: Blood Adv Date: 2021-03-23
Authors: Manoj Menon; Anna Coghill; Innocent Mutyaba; Fred Okuku; Warren Phipps; John Harlan; Jackson Orem; Corey Casper Journal: PLoS One Date: 2018-02-01 Impact factor: 3.240